Neuropathic pain is a chronic pain condition caused by lesion or disease affecting the somatosensory system. The glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs) alleviate symptoms of NP and stimulate regeneration of sensory neurons in vivo. Here we report the development of the compound BT18 that selectively activates GFL receptors, alleviates pain and restores damaged dorsal root ganglion (DRG) neurons in rat models of NP.
Introduction
Neuropathic pain (NP) affects millions of people yet existing therapies manage it poorly, do not remedy the underlying cause and have significant side effects. NP often accompanies physical trauma, chemotherapy treatment and diabetes (1) (2) (3) .
GFLs are neurotrophic factors that support survival, regeneration and functioning of several neuronal populations: dopaminergic, enteric, sympathetic, parasympathetic, motor, cholinergic neurons and of sensory neurons. GFLs bind to the GDNF family receptor α (GFRα), which provides ligandbinding selectivity, and signal via a receptor tyrosine kinase (RTK) RET. GDNF preferentially binds to GFRα1 and ARTN to GFRα3 (Supplementary Fig. 1a ). Ligand binding to GFRα/RET receptor complex stimulates RET phosphorylation and activation of intracellular signaling cascades including MAPK, PI3K/Akt, PLCγ, Src that are important for neuronal functionality (reviewed in (4); Supplementary Fig.   1b ).
GDNF and artemin (ARTN) both can reverse neurological damage produced by lesion in animal models of NP (5) (6) (7) (8) . However, these proteins have poor pharmacological properties to be administered systemically (4, 9) .
Using cell-based high-throughput screening we discovered novel family of compounds that could activate RET and induce its downstream signaling. We optimized the hit compounds to improve their potency an bioavailability and demonstrated that the compound termed BT18 could activate RET but no other tested RTKs in vitro, alleviated symptoms of NP in vivo and restored damaged DRG neurons in rat models of NP.
Results
To identify small molecular weight GFL mimetics, we first made stable cell lines expressing GFL receptors and luciferase reporter that is induced by MAPK signaling (10) (Supplementary Fig. 1b ). We screened 18000 diverse drug-like compounds using reporter cell line expressing GFRα1/RET, identifying 43 hits that increased luciferase activity at least three fold. We reconfirmed biological activity of five and further validated after re-synthesis two of them, both having a similar chemical structure, using the same luciferase-reporter assay. The hit-compound named BT13 (Supplementary Table 1 ; Fig.   1a ) potently induced luciferase activity in reporter cell line, induced RET phosphorylation and RETdependent intracellular signaling in GFRα1/RET-expressing cells ( Supplementary Fig. 2 ) and it was chosen for future development. We found that BT13 also efficiently activated luciferase reporter in ARTN-responding GFRα3/RET-expressing cells (Fig. 1b) and less so in RET-only-expressing cells (Fig.   1a ).
To improve the pharmacological properties of BT13 (effective concentration eliciting 50% of activation (EC50) in luciferase reporter assay in GFRα1/RET cells is 13µM) we synthesized compounds BT16, BT17 and BT18 with predicted improved activity towards GFRα/RET (Supplementary Table 1 ).
We found that BT17 and BT18 indeed activated luciferase more potently than the original compound in both GFRα1/RET and GFRα3/RET lines (EC50 = 3 and 7 µM, in GFRα1/RET respectively) with almost no activity in RET-only expressing cells (Fig. 1a, b) . All four compounds increased the level of RET phosphorylation in MG87RET fibroblasts expressing GFRα3 but also in cells lacking GFRα ( Supplementary Fig. 3a) . BT18 was the most active in RET phosphorylation assay in both cell lines and had insignificant acute toxicity to immortalized ( Supplementary Fig. 3b ) and primary murine fibroblasts ( Supplementary Fig. 3c ). We confirmed that BT18 dose-dependently increased phosphorylation of RET ( Fig. 1c) and its downstream targets, Akt and ERK (Fig. 1d) , in the presence and absence of overexpressed GFRα3 in MG87RET fibroblasts. We selected BT18 for further studies.
To elucidate the mechanism of BT18-induced RET activation we assessed direct binding of BT18 to GFL receptors. BT18 at 50 µM reduced binding of radioiodinated GDNF ( 125 I-GDNF), which binds both GFRα1/RET and GFRα3/RET, in cells expressing GFRα1/RET ( Supplementary Fig. 4a ), suggesting binding of GFL and mimetic to the same site. Since, GFRα appears to be dispensable for BT18 activity we attempted computational docking of the compound to RET at the site GDNF (and likely ARTN) interacts with RET (11). We found that BT18 can be docked to cysteine-rich domain (CRD) of RET ( Supplementary Fig. 4b ). In addition, RET downstream signaling can be induced by BT18 with fast kinetics, mimicking that of GDNF ( Supplementary Fig. 4c ). Together with 125 I-GDNF displacement results and molecular docking this suggests a direct interaction of BT18 with RET, leading to productive RET signaling.
In addition to RET nociceptive sensory neurons express other RTKs such as neurotrophin receptors
TrkA and TrkB (12) . Since activation of TrkA and TrkB by their natural ligands, nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), was shown to increase pain (13, 14) , we tested the ability of BT18 to phosphorylate TrkA and TrkB and their downstream targets Akt and ERK ( Fig. 1e-h) using MG87TrkA and MG87TrkB fibroblasts. We also assessed levels of pAkt and pERK upon BT18 administration in parental MG87 cells (Fig. 1h ) lacking receptors for neurotrophic factor but expressing other RTKs, for example, fibroblast growth factor (FGF) receptors. BT18 neither activates TrkA (Fig. 1e) , TrkB ( Fig. 1f) nor ERK in the absence of RET (Fig. 1g, h ). In addition, no activation of Akt was observed in MG87TrkB and MG87 parental cells in response to BT18 (Fig. 1h) . However, in some experiments, BT18 elicited marginal and transient increase of pAkt level in MG87TrkA cells ( Supplementary Fig. 5A ). Taken together, our data indicate that BT18 is a selective RET agonist.
We then tested the ability of BT18 to mimic GFL activity in neurons and to stimulate neurite outgrowth from P1-P3 mouse DRG neurons. BT18 (0.5-1 μM) increased the number of neurite-bearing DRG neurons by approximately 30% in vitro (Fig. 1i, Supplementary Fig. 6 ).
We assessed absorption, distribution, metabolism and excretion (ADME) properties of BT18 (Supplementary Table 2 ) and considered the therapeutic window and the safety profile of BT18 satisfactory for testing in animal models of NP ( Fig. 2a-e) . Subcutaneous BT18 attenuated hyperalgesia/allodynia and increased thresholds of mechanical nociception of the ipsilateral paw in both the chronic constriction injury (CCI; Bennett, Fig. 2a , c, d) (15) and the spinal nerve ligation (SNL;
Chung, Fig. 2a , c, e) (16) models of NP. The effect was statistically significant at doses above 5 mg/kg (Fig. 2e, d ). Importantly, BT18 did not affect mechanical (Fig. 2f ) sensitivity and motor performance ( Fig. 2g ) in non-neuropathic rats, indicating that its analgesic effect is specific for NP and not caused by sedation or impaired coordination. BT18 did not influence weight gain ( Supplementary Fig. 7a ), and no other signs of toxicity were observed during its administration.
Since ARTN induced cold allodynia and thermal hyperalgesia in non-neuropathic rodents (17, 18),
we assessed the effect of BT18 on thermal sensitivity in healthy rats, using acetone, hot-plate and tailflick tests. BT18 neither provoked cold allodynia (Fig. 2h ) nor induced tail-flick thermal hyperalgesia ( Supplementary Fig. 7b ), which might be explained by the selectivity of BT18 towards RET as the effect of ARTN protein on cold sensitivity is not RET-mediated (18). In the hot-plate test, however, BT18
produced some hyperalgesic effect ( Supplementary Fig. 7c ), as in earlier studies on ARTN (17, 18) .
Similarly to ARTN (6), BT18 restored expression of different neuronal markers in DRGs (IB4, CGRP, NpY) and sciatic nerve (NaV1. We analyzed expression of RET, GFRα1, GFRα2 and GFRα3 mRNAs in DRGs of animals with SNL by qPCR since immunological methods using control tissues from respective knockout animals failed to produce reliable results. In line with earlier protein expression data (6), we observed an increase in GFRα3 mRNA level after SNL that was affected by neither ARTN nor BT18. However, in our study, SNL led to a marked decrease in RET expression that was restored by BT18 but not by ARTN. In addition, BT18 increased mRNA levels of GFRα1 but did not affect GFRα2 expression in DRGs of animals with experimental neuropathy (Fig. 3d ).
Discussion
Our results show that BT18 mimics the action of ARTN and GDNF in vitro and in vivo by activating RET. BT18 stimulates neurite outgrowth from cultured DRG neurons, alleviates NP manifestations in animal models and reverses surgery-induced changes in the expression of multiple neuronal markers in rat models of experimental neuropathy.
The microsomal stability of BT18 (t1/2 < 30 min) and its lifespan in serum (t1/2 = 41.7 min) are short (Supplementary Table 2 ). Therefore, in vivo BT18 is likely to activate RET transiently, which can prevent problems associated with chronic RET activation, such as possible tumor formation. In addition, BT18
has limited blood-brain permeability, reducing its potential for cerebral toxicity.
The mechanism of BT18 action warrants further study. Unlike natural ligands of RET (the GFLs), BT18 stimulates RET-dependent response even in the absence of co-receptor GFRα. In an active receptor complex the GDNF makes a direct contact with membrane-proximal domain of RET (11) and ARTN is likely to bind GFRα3/RET in the same manner. Our docking data indicate that BT18 can bind RET directly at the same site as do GDNF/ARTN ( Supplementary Fig. 4 ). This may result in a conformational change seen in other RTK, leading to productive RET signaling (4) . The hypothesis suggesting the direct interaction of BT18 and RET is supported by kinetics of RET activation by BT18
and by the displacing of radiolabeled GDNF from cells expressing GFRα1/RET by BT18
( Supplementary Fig. 4 ). Further biochemical experiments with labelled ARTN and purified components of the GFRα3/RET complex are required to elucidate the exact mechanism of BT18 action.
The previously described compound, XIB4035 (20), modulating GFRα/RET signaling and alleviating pain symptoms in small-fiber neuropathy animal model could not activate RET in the absence of GFL and is, therefore, could not be considered as RET agonist.
In summary, BT18 is the first described RET small molecule agonist that significantly attenuates pain behavior, restores molecular changes caused by experimental nerve injury in peripheral neurons in vivo and thus opens a way to develop novel disease-modifying drugs for neuropathic pain treatment. (16)). Before operation, the rats were tested for sensitivity to mechanical stimuli using von Frey (VF) filaments. Animals with a paw withdrawal threshold (PWT) below 12 g were excluded from the study. Rats were subsequently balanced and assigned to treatment groups based on their pre-operative PWT values. Surgery was performed under isoflurane anesthesia. All rats received an analgesic (buprenorphine, 0.05 mg/kg, subcutaneously)
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immediately before and 6 h after surgery. Each rat was monitored until it was awake and moving freely around the recovery chamber. Animals were then single-housed for the duration of the study. Behavioral tests. Sensitivity of the rats with experimental neuropathy to mechanical stimuli was determined using VF filaments on the 12 th day after surgery. VF filaments of increasing bending force were applied to the plantar surface of the hind paw. Pressure required to elicit withdrawal of the paw was determined.
In non-neuropathic rats, we assessed cold sensitivity, acute nociception and motor coordination using the acetone test (AC), tail-flick (TF), hot plate (HP), paw pressure (PP), and rotarod (RR) apparatuses (Ugo Basile, Comerio, Italy, device models 37360, 35100, 37215, and 47700, respectively).
We measured baseline responses on the 1 st day of the experiment, 1 h before the administration of the test compounds. Consequently, animals were divided into two balanced groups according to weight and nociceptive baselines. The experiments were performed in a randomized and blinded fashion.
To measure sensitivity to thermal stimuli, we used TF and HP tests. For the TF test, the infrared light was directed in turn to three different points of the middle third of the tail of a constrained animal.
For the HP test, the rat was put on a hot plate adjusted to 52°C (± 0.2°C). Latency time before the TF or licking or brisk shaking of the hind paw or jumping was assessed and cut-off times of 7 TF and 60 s HP were used to prevent tissue damage. Sensitivity to mechanical stimuli was measured with the PP test.
The left hind paw of the constrained rat was placed under a pivot and the force applied to the paw was linearly increased. Vocalization or brisk shaking of the hind limb was used as a behavioral sign of nociception and the measurement was terminated. The force causing the behavioral response was recorded. The cut-off was set to 500 g. To assess motor coordination, the time during which the animal was able to stay on the rotating rod (20 rpm, fixed speed) was measured and a cut-off time of 30 s was used. Cold allodynia was assessed using the AC (18). The animals were placed in an elevated plexiglass chamber with a mesh floor and allowed to acclimatize for 5 min. A drop of acetone was applied to the plantar surface of the hind paw three times with 3-min intervals between the measurements, alternating paws between stimulations. A brisk withdrawal, shaking or licking of the hind limb were considered as responses of cold allodynia and their number was recorded.
Phosphorylation assays. Phosphorylation of receptor tyrosine kinase RET, TrkA, TrkB in cultured cells was assessed by antibodies against phosphorylated tyrosine residues (clone 4G10, Upstate)
after immunoprecipitation of RTKs with specific antibodies targeted to RET or TrkA/TrkB, respectively.
Phosphorylation of intracellular signaling proteins ERK and AKT was determined using specific antibodies against phosphorylated forms of the respective proteins.
Cytotoxicity assays. To assess the ability of our compounds to influence proliferation of immortalized (MG87 murine fibroblasts) and primary non-neuronal cells (embryonic fibroblasts), we used AlamarBlue dye (Life Technologies) or CellTiterGlo (Promega).
125 I-GDNF displacement assay. GDNF was enzymatically iodinated by lactoperoxidase as described (21). Cells were treated with 5-100 µM BT18 or 5 nM unlabelled GDNF and 50 pM of 125 I-GDNF dissolved in blocking solution and incubated for 2 h on ice, washed and lysed with 1 M NaOH.
Lysates were transferred to vials and counted on a Wallac Gamma Counter (Wallac/LKB). ADME-Tox profiling. ADME profiling was performed by CRO Cyathus Exquirere (Milan, Italy).
To assess BT18 pharmacokinetics, 10 mg/kg of BT18 were intravenously injected into nine male Sprague Dawley rats. Plasma and brain samples were collected 1, 3 and 6 h later.
Immunohistochemistry. Sections of sciatic nerves and DRGs from rats with spinal nerve ligation and treated with BT18 or vehicle were probed, after deparaffinization and acidic or basic antigeneretrieval using standard IHC protocols, with antibodies against NaV1. Proteins. GDNF, ARTN, BDNF were obtained from PeproTech Ltd. NGF was purchased from
Promega. Concentration of all GFLs was checked by microBCA kit (Pierce) using BSA as a standard.
Plasmids. Fulllength human GFR α 1 cDNA subcloned in pCDNA6 (Invitrogene; USA), fulllength human GFR α 3 cDNA (was a gift of Prof. Jeff Milbrandt), fulllength human RET (long isoform) in pCR3.1 (Invitrogen), PathDetect Elk1 system (Stratagene, USA).
High throughput luciferase assays
To select GFL mimetics, we used a previously developed reportergenebased luciferase assay (12) . The principle of this assay is described in Supplementary Fig. 1b . We used MG87 murine fibroblasts stably transfected with Pathdetect Elk1 (Stratagene) and one of the following: RET, GFR α 1/RET, GFR α 1/RET. High throughput screening was performed using chemicals in a single concentration (5 μ M) and single dose. The compounds were dissolved in DMSO to 5 mM concentration, transferred to 384well storage plates (Greiner) and kept at room temperature (RT) in a desiccator before the experiment. The day before the experiment, the GFR α 1/RET reporter cells were plated into 384well cell culture plates (PerkinElmer) at 175 000 cell/ml density using an automatic liquid dispenser (Thermo) in 50 μ l DMEM, 10% FBS, 100 µ g/ml Normocin (Invivogen), 1% DMSO, 15 mM Hepes, pH 7.2. The next day, approximately 50 nl of each compound was delivered into the individual wells using a pintool equipped robotic workstation (Beckman Coulter). The following day, the cells were lysed using the luciferase detection reagent (SteadyGlo, Promega). Ten minutes after the reagent addition, the luminescence was measured on a TopCount luminometer (PerkinElmer).
The hit confirmation experiments, screening of focused library were performed in 96well format in four replicas and several concentrations. For detection of luciferase activity, we used luciferase assay reagent (Promega) and did measurements on MicroBeta 2 counter (PerkinElmer).
Phosphorylation assays
Phosphorylation of receptor tyrosine kinase RET, TrkA, TrkB in cultured cells was assessed by antibodies against phosphorylated tyrosine residues (clone 4G10, Upstate) after immunoprecipitation of To quantitatively assess the level of RET phosphorylation we used a sandwichELISA based method developed by us (RETELISA). Highbinding capacity 96well black OptiPlates (PerkinElemer) were precoated overnight at +4 º C with antiRET antibodies (1 μ g/ml in 1xPBS, 75 μ l/well) and unbounded antibodies were washed away by three changes of 1x PBS. To prevent nonspecific interactions, plates were blocked in 5% BSA in 1x TBS (400 μ l/well) for 3 h at RT.
Afterwards, plates were washed once with RIPA buffer, incubated with cell lysates (75 μ l/well) overnight at +4 º C and washed three times. Then, plates were incubated with antiphosphotyrosine antibodies (100 μ l/well, clone 4G10, Upstate Biotechnology) diluted 1:1000 in binding buffer (1xTBS, 1% Triton X100, 2% glycerol, 2% BSA) for 12 h at RT. Plates were washed three times with washing buffer (400 μ l/well, 1x TBS, 1% Triton X100, 2% glycerol) and incubated with secondary antibodies (100 μ l/well 1:1000 antimouse antibodies conjugated with HRP (DAKO), diluted in binding buffer.
Plates were washed three times with washing buffer. Prewarmed Femto ECL reagent (Pierce) was added to the wells (100 μ l/well). Luminescence was measured using MicroBeta 2 counter (PerkinElmer).
Whole cell lysates were resolved on 12% SDSPAGE and transferred to nitrocellulose membranes. Membranes were blocked in 10% nonfat dry milk in TBST for 1015 min and probed 
Cytotoxicity assays.
To assess the ability of our compounds to influence proliferation of immortalized (MG87 murine fibroblasts) and primary nonneuronal cells (embryonic fibroblasts), we used AlamarBlue dye (Life Technologies) or CellTiterGlo (Promega). Before execution, the assay was optimized for plating cell density and length of the incubation with the dyes for each cell batch. Experiments were performed on MG87 murine fibroblasts and primary embryonic fibroblasts. To assess cell proliferation with AlamarBlue dye, cells were plated on 96well CulturPlates (PerkinElmer) in 100 µ l of DMEM, containing 10% FBS, 1% DMSO and 100 µ g/ml Normocin 24 h prior assay. Compounds were dissolved in DMEM, containing 1% DMSO (final), 15 mM Hepes, pH 7.2, until 2x concentration (50 and 200 µ M) and 100 µ l of the solution was added to the cells. MG87 cells were incubated with compounds for another 24 h, embryonic fibroblasts -for 72 h. Afterwards, media were aspirated and replaced with phenol redfree DMEM containing 10% FBS, 100 µ g/ml Normocin, and 10%
AlamarBlue for 4 h. Fluorescence was detected using plate fluorimeter (Envision or Victor III Reader, PerkinElmer) with excitation wavelength 530560 nm and emission 590 nm. Cell density was calculated from fluorescence intensity using calibrating plot.
Assessment of cell proliferation with CellTiterGlo reagent was performed according to the manufacturing instructions on 384well plates in the same culturing conditions as described for
AlamarBlue. In both cases, the signal from the wells with cells treated with vehicle (1% DMSO in DMEM, 15 mM Hepes, pH 7.2) was considered as 100%.
125
IGDNF displacement assay
The labelling reaction was performed at RT in a final volume of 50 μ l. Results are presented as Mean ± SEM of five independent experiments.
Neurite outgrowth from DRG neurons
DRG ganglia were dissected from P1P3 newborn mice in PBS under a dissection microscope.
Ganglia were cleaned from nerve fibers, transferred to a centrifuge tube and washed twice with HBSS.
To prepare dissociated neuronal cultures, ganglia were incubated in trypsin (10 mg/ml) for 20 min at 
ADMETox profiling
ADME profiling was performed by CRO Cyathus Exquirere (Milan, Italy). To assess BT18 pharmacokinetics, 10 mg/kg of BT18 were intravenously injected into nine male Sprague Dawley rats.
Plasma and brain samples were collected 1, 3 and 6 h later. Plasma stability of BT18 was assessed after 1 h incubation with human, rat and mouse plasma, using verapamil as internal standard and lidocaine and M7319 (Sigma) as reference compounds. Metabolic stability of BT18 was measured after 30 min incubation with 0.5 mg/ml of rat liver microsomes (Xenotech) using verapamil as internal standard and 7ethoxycoumarin and propranolol as reference standards. In all abovementioned cases, samples were analyzed by chromatography on an UPLC system integrated with a Premiere XE Triple. To assess cardiac safety of BT18 we measured its K i in competition assay with radiolabelled ligand of the hERG (human Ether à gogorelated gene) [ CYP2C9, CYP2C19, CYP2D6 and CYP3A4) was measured using a fluorescent assay with specific substrate for each isoenzyme. The IC 50 was determined using a fourparameter curve fit. Furafylline, sulfaphenazole, tranylcypromine, quinidine and ketoconazole were used as reference compounds for
CYPs listed above.
